The Endo International PLC (ENDP) Rating Lowered to Neutral at JPMorgan Chase & Co.

The Endo International PLC (ENDP) Rating Lowered to Neutral at JPMorgan Chase & Co.

Endo International PLC (NASDAQ:ENDP) was downgraded by stock analysts at JPMorgan Chase & Co. from an “overweight” rating to a “neutral” rating in a research note issued to investors on Friday.

A number of other analysts have also issued reports on the company. Northland Securities upgraded Endo International PLC from a “market perform” rating to an “outperform” rating and set a $27.00 target price for the company in a report on Thursday, September 29th. Mizuho restated a “sell” rating and issued a $29.00 target price on shares of Endo International PLC in a report on Thursday, September 29th. Oppenheimer Holdings Inc. restated a “market perform” rating on shares of Endo International PLC in a report on Tuesday, September 27th. Piper Jaffray Cos. restated a “neutral” rating and issued a $19.00 target price on shares of Endo International PLC in a report on Tuesday, September 27th. Finally, Vetr upgraded Endo International PLC from a “buy” rating to a “strong-buy” rating in a report on Friday, October 21st. One investment analyst has rated the stock with a sell rating, eleven have given a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company. Endo International PLC currently has an average rating of “Buy” and an average price target of $29.95.

Shares of Endo International PLC (NASDAQ:ENDP) opened at 12.90 on Friday. The firm’s 50-day moving average price is $15.53 and its 200-day moving average price is $18.44. The stock’s market cap is $2.88 billion. Endo International PLC has a 52-week low of $12.56 and a 52-week high of $61.14.

Endo International PLC (NASDAQ:ENDP) last announced its quarterly earnings data on Tuesday, November 8th. The company reported $1.01 EPS for the quarter, beating analysts’ consensus estimates of $0.81 by $0.20. Endo International PLC had a positive return on equity of 15.95% and a negative net margin of 3.32%. The company earned $894.30 million during the quarter, compared to the consensus estimate of $862.47 million. During the same quarter in the prior year, the firm earned $1.02 EPS. The company’s quarterly revenue was up 18.6% compared to the same quarter last year. On average, equities research analysts forecast that Endo International PLC will post $4.59 earnings per share for the current fiscal year.

In other Endo International PLC news, Director Roger H. Kimmel sold 14,000 shares of the firm’s stock in a transaction dated Tuesday, November 15th. The shares were sold at an average price of $17.38, for a total transaction of $243,320.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. 0.70% of the stock is owned by company insiders.

Hedge funds and other institutional investors have recently made changes to their positions in the company. Marshall Wace LLP boosted its position in shares of Endo International PLC by 814.0% in the second quarter. Marshall Wace LLP now owns 73,821 shares of the company’s stock worth $1,151,000 after buying an additional 65,744 shares in the last quarter. Van ECK Associates Corp boosted its position in Endo International PLC by 54.1% in the second quarter. Van ECK Associates Corp now owns 117,695 shares of the company’s stock worth $1,835,000 after buying an additional 41,331 shares during the period. State Street Corp boosted its position in Endo International PLC by 9.3% in the second quarter. State Street Corp now owns 9,430,866 shares of the company’s stock worth $147,021,000 after buying an additional 805,101 shares during the period. American National Insurance Co. TX boosted its position in Endo International PLC by 10.8% in the second quarter. American National Insurance Co. TX now owns 126,880 shares of the company’s stock worth $1,978,000 after buying an additional 12,410 shares during the period. Finally, Tredje AP fonden boosted its position in Endo International PLC by 123.3% in the second quarter. Tredje AP fonden now owns 57,835 shares of the company’s stock worth $902,000 after buying an additional 31,935 shares during the period. Hedge funds and other institutional investors own 93.31% of the company’s stock.

Endo International PLC Company Profile

Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.

Related posts

Leave a Comment